Imperial College London
Alternate

Professor Sir Roy Anderson FRS, FMedSci

Faculty of Medicine, School of Public Health

Professor in Infectious Disease Epidemiology
 
 
 
//

Contact

 

roy.anderson Website

 
 
//

Assistant

 

Mrs Clare Mylchreest +44 (0)7766 331 301

 
//

Location

 

LG35Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Lochen:2020:10.1038/s41598-020-75691-5,
author = {Lochen, A and Croucher, N and Anderson, R},
doi = {10.1038/s41598-020-75691-5},
journal = {Scientific Reports},
title = {Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency},
url = {http://dx.doi.org/10.1038/s41598-020-75691-5},
volume = {10},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Streptococcus pneumoniae is a significant cause of otitis media, pneumonia, and meningitis. Only seven of the approximately 100 serotypes were initially included in the pneumococcal conjugate vaccine (PCV) in 2000 before it was expanded in subsequent years. Although the invasive pneumococcal disease (IPD) incidence due to vaccine serotypes (VT) has declined, partial replacement by non-vaccine serotypes (NVT) was observed following widespread vaccine uptake. We conducted a trend analysis assembling all the available evidence for PCV impact on European, North American and Australian national IPD. Significant effectiveness against VT IPD in infants was observed, although the impact on national IPD incidence varied internationally due to serotype replacement. Currently, NVT serotypes 8, 9N, 15A and 23B are increasing in the countries assessed, although a variety of other NVTs are affecting each country and age group. Despite these common emerging serotypes, there has not been a dominant IPD serotype post-vaccination as there was pre-vaccination (serotype 14) or post-PCV7 (serotype 19A), suggesting that future vaccines with additional serotypes will be less effective at targeting and reducing IPD in global populations than previous PCVs. The rise of diverse NVTs in all settings’ top-ranked IPD-causing serotypes emphasizes the urgent need for surveillance data on serotype distribution and serotype-specific invasiveness post-vaccination to facilitate decision making concerning both expanding current vaccination programmes and increasing vaccine valency.
AU  - Lochen,A
AU  - Croucher,N
AU  - Anderson,R
DO  - 10.1038/s41598-020-75691-5
PY  - 2020///
SN  - 2045-2322
TI  - Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency
T2  - Scientific Reports
UR  - http://dx.doi.org/10.1038/s41598-020-75691-5
UR  - http://hdl.handle.net/10044/1/84714
VL  - 10
ER  -
Download